

TOGETHER, WE CAN START ON A NEW PATH TO TREATING ALZHEIMER'S DISEASE.

A research study for a potential new treatment for Alzheimer's disease is looking for qualified people to enroll.

The **START (Synaptic Therapy Alzheimer's Research Trial)** Study is testing an investigational treatment to see if it can safely slow memory loss from Alzheimer's disease (AD). It lasts about two years and you will be asked to make about 24 visits to the study site to see doctors who will closely monitor your health. By participating, you or your loved one could be an important part of finding new treatments for people with AD.

TO QUALIFY FOR THE STUDY, YOU OR YOUR LOVED ONE MUST:

- ✔ Be between 50 and 85 years old.
- ✔ Have a diagnosis of mild AD dementia, OR a diagnosis of mild cognitive impairment (MCI) due to AD, OR memory concerns noticed by another person.
- ✔ Have a study partner who can come with you to some visits and take part in some testing.

There are more requirements to qualify for the START Study. The screening process includes testing. Someone on the study team can discuss the testing with you.



START

To learn more about the **START Study**, visit START-Study.org or call **1-833-START-33**.

STUDY SITE INFORMATION

Sanders-Brown Center
on Aging

Contact: 859-323-1331

ACTC
ALZHEIMER'S
CLINICAL TRIALS CONSORTIUM

COGNITION
Therapeutics

Study Sponsors and Leadership: The START Study is funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH) and sponsored by Cognition Therapeutics. The study is being conducted by the NIH-funded Alzheimer's Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer's research centers.

The study is led by Alzheimer's disease research experts and academic leadership at the ACTC, Yale School of Medicine, and Cognition Therapeutics.